Table 1

Published clinical experience of MSC immune modulation

Autoimmune diseasePatients (N)MSC productRouteOutcomesReferences
Acute GvHD1Allogeneic bone marrowIVIImproved skin, gut and liverLe Blanc et al20
Acute GvHD55Allogeneic bone marrowIVI30 ImprovedLe Blanc et al8
Scleroderma1Allogeneic bone marrowIVIImprovedChristopeit et al21
Multiple sclerosis10Allogeneic bone marrowIntrathecalMixed responsesM22
Multiple sclerosis3Mixed allogous and autologous fatMixed IVI and intrathecalImproved clinical findings, MRI unchangedMohyeddin Bonab et al23
Crohn's fistulae4Autologous fatIntrafistula75% ClosureRiordan et al24
Lupus nephritis4Allogeneic bone marrowIVIImproved SLEDAI and proteinuriaSun et al12
Lupus nephritis16Allogeneic umbilical cordIVIImproved SLEDAI and renal functionSun et al25
Systemic lupus erythematosus2Autologous bone marrowIVINo changeCarrion et al13
  • GvHD, graft versus host disease; IVI, intravenous injection; MSC, mesenchymal stem cell; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.